VCAM-1/CD106 Antibody [Unconjugated]

HAF016). A specific band was detected for VCAM-1/CD106 at approximately 100 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." > HAF016). A specific band was detected for VCAM-1/CD106 at approximately 100 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." title="Western blot shows lysates of 786-O human renal cell adenocarcinoma cell line. PVDF membrane was probed with 2 µg/mL of Sheep Anti-Human VCAM-1/ CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for VCAM-1/CD106 at approximately 100 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." />

Western blot shows lysates of 786-O human renal cell adenocarcinoma cell line. PVDF membrane was probed with 2 µg/mL of Sheep Anti-Human VCAM-1/ CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # <a class=

210-TA) for 24 hrs, loaded at 0.2 mg/mL. A specific band was detected for VCAM‑1/CD106 at approximately 132 kDa (as indicated) using 20 µg/mL of Sheep Anti-Human VCAM‑1/CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) followed by 1:50 dilution of HRP-conjugated Anti-Sheep IgG Secondary Antibody (HAF016). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." > 210-TA) for 24 hrs, loaded at 0.2 mg/mL. A specific band was detected for VCAM‑1/CD106 at approximately 132 kDa (as indicated) using 20 µg/mL of Sheep Anti-Human VCAM‑1/CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) followed by 1:50 dilution of HRP-conjugated Anti-Sheep IgG Secondary Antibody (HAF016). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." title="Simple Western lane view shows lysates of HUVEC human umbilical vein endothelial cells untreated (-) or treated (+) with 10 ng/ml Recombinant Human TNF‑ alpha (210-TA) for 24 hrs, loaded at 0.2 mg/mL. A specific band was detected for VCAM‑1/CD106 at approximately 132 kDa (as indicated) using 20 µg/mL of Sheep Anti-Human VCAM‑1/CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) followed by 1:50 dilution of HRP-conjugated Anti-Sheep IgG Secondary Antibody (HAF016). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." />

Simple Western lane view shows lysates of HUVEC human umbilical vein endothelial cells untreated (-) or treated (+) with 10 ng/ml Recombinant Human TNF‑ alpha (<a class=

Inhibition of ICAM-1- and VCAM-1-mediated cell adhesion reduces T-ALL burden in vivo. A Experimental schematic depicting dosing schedule for anti-ICAM-1, anti-VCAM-1, or isotype control antibodies following establishment of LN3 T-ALL ( > 1% spleen chimerism) in congenic hosts. Leukemia burden was assessed 2 days after the final antibody injection. b Quantification of spleen and liver weights from the experiments depicted in (a). Tumor-free, age-matched mice were included for comparison. Bars depict the mean + SEM of cumulative data from n = 5 experiments, each with a distinct color-coded primary T-ALL; symbols represent individual mice. c Representative flow cytometry plots showing a decrease in T-ALL burden in the spleens of LN3 T-ALL-transplanted mice following treatment with anti-ICAM-1 +/- anti-VCAM-1 antibodies (100 µg each per mouse). d, e Quantification of the (d) frequency of circulating T-ALL blasts in the blood and (e) number of T-ALL cells in the spleen, BM, LN, and liver from the same experiments as in (b). f Quantification of the indicated myeloid subsets or TCR beta + or B220+ host cells in the spleens of mice from the same experiments as in (d, e). Statistical significance was determined by (b, d, e, f) a two-sided repeated measures one-way ANOVA with the Holm-Sidak correction; P-values: *<0.05, **<0.01, ***<0.001. ns, not significant. Source data are provided as a Source Data file. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37805579), licensed under a CC-BY license. Not internally tested by R&D Systems.

809-VR) was serially diluted and captured by Mouse Anti-Human VCAM‑1/CD106 Monoclonal Antibody (Catalog # MAB809) coated on a Clear Polystyrene Microplate (Catalog # DY990). Sheep Anti-Human VCAM‑1/CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" > 809-VR) was serially diluted and captured by Mouse Anti-Human VCAM‑1/CD106 Monoclonal Antibody (Catalog # MAB809) coated on a Clear Polystyrene Microplate (Catalog # DY990). Sheep Anti-Human VCAM‑1/CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" title="Recombinant Human VCAM‑1/CD106 (Catalog # 809-VR) was serially diluted and captured by Mouse Anti-Human VCAM‑1/CD106 Monoclonal Antibody (Catalog # MAB809) coated on a Clear Polystyrene Microplate (Catalog # DY990). Sheep Anti-Human VCAM‑1/CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" />

Recombinant Human VCAM‑1/CD106 (Catalog # <a class=

• Reactivity: Hu
• Applications: WB, Simple Western, B/N
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Unconjugated
• Concentration: LYOPH

VCAM-1/CD106 Antibody [Unconjugated] Summary

• Immunogen: Chinese hamster ovary cell line (CHO)-derived recombinant human VCAM-1
  Extracellular domain
• Specificity: Detects VCAM-1 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse VCAM-1 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Gene: VCAM1
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Adhesion Blockade
  • Simple Western 20 ug/mL
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VCAM-1/CD106 Antibody [Unconjugated]

• CD106 antigen
• CD106
• DKFZp779G2333
• INCAM-100
• L1CAM
• MGC99561
• vascular cell adhesion molecule 1
• vascular cell adhesion protein 1
• V-CAM 1
• VCAM1
• VCAM-1

Background

VCAM-1 (CD106), a member of the immunoglobulin superfamily, is a cell surface protein expressed by activated endothelial cells and certain leukocytes (such as macrophages). VCAM-1 expression is induced by IL-1 beta , IL-4, TNF-alpha , and IFN-gamma . VCAM-1 binds to leukocyte integrins VLA-4 and alpha ₄ beta ₇. The human and mouse VCAM-1 proteins share approximately 76% amino acid similarity.

During the inflammatory adhesion mechanism, activated integrins halt rolling leukocytes and attach them firmly to the vascular endothelium. They do this by binding to their ligands, for example VCAM-1, on endothelium. The VCAM-1: VLA-4/ alpha ₄ beta ₇ interaction is also thought to be involved in the extravasation of white blood cells through the blood vessel wall to sites of inflammation.

ELISA techniques have shown that detectable levels of soluble VCAM-1 are present in the biological fluids of apparently normal individuals. Furthermore, a number of studies have reported that levels of VCAM-1 may be elevated or lowered in subjects with a variety of pathological conditions.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VCAM-1/CD106 Antibody (AF809)(10)

Publications using AF809

• Lyu, A;Humphrey, RS;Nam, SH;Durham, TA;Hu, Z;Arasappan, D;Horton, TM;Ehrlich, LIR; Integrin signaling is critical for myeloid-mediated support of T-cell acute lymphoblastic leukemia Nature communications 2023-10-07 [PMID: 37805579] (Bioassay, Flow Cytometry, Human)
• Ye Ran, Yankai Dong, Yuejiao Li, Jundong Xie, Shubin Zeng, Chuanlei Liang et al. Mesenchymal stem cell aggregation mediated by integrin alpha 4/VCAM-1 after intrathecal transplantation in MCAO rats Stem Cell Research & Therapy 2022-10-22 [PMID: 36273220]
• Hideaki Nishihara, Sasha Soldati, Adrien Mossu, Maria Rosito, Henriette Rudolph, William A. Muller et al. Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro Fluids and Barriers of the CNS 2020-12-01 [PMID: 32008573]
• Rivera-Serrano EE, Gonzalez-Lopez O, Das A, Lemon SM. Cellular entry and uncoating of naked and quasi-enveloped human hepatoviruses Elife 2/25/2019 [PMID: 30801249]
• Tsagogiorgas C, Wedel J, Hottenrott M, Schneider M, Binzen U, Greffrath W, Treede R, Theisinger B, Theisinger S, Waldherr R, Kramer B, Thiel M, Schnuelle P, Yard B, Hoeger S N-octanoyl-dopamine is an agonist at the capsaicin receptor TRPV1 and mitigates is chemia-induced acute kidney injury in rat. PLoS ONE, 2012-08-20;7(8):e43525. 2012-08-20 [PMID: 22916273] (Western Blot, Human)
• Teo G, Ankrum J, Martinelli R, Boetto S, Simms K, Sciuto T, Dvorak A, Karp J, Carman C Mesenchymal Stem Cells Transmigrate Between and Directly Through Tumor Necrosis Factor-alpha-Activated Endothelial Cells Via Both Leukocyte-Like and Novel Mechanisms. Stem Cells, 2012-11-01;30(11):2472-86. 2012-11-01 [PMID: 22887987] (ICC, Neutralization, Human)
• Zhao X, Qureshi F, Eastman PS, Manning WC, Alexander C, Robinson WH, Hesterberg LK Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. J. Immunol. Methods, 2012-02-17;378(1):72-80. 2012-02-17 [PMID: 22366959] (ELISA Development, Human)
• Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum., 2007-06-01;56(6):1817-26. 2007-06-01 [PMID: 17530710] (Neutralization, Western Blot, Human)
• Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP, Koch AE Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood, 2005-11-29;107(6):2252-61. 2005-11-29 [PMID: 16317091] (ICC, Western Blot, Human)
• Carman CV, Springer TA A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J. Cell Biol., 2004-10-25;167(2):377-88. 2004-10-25 [PMID: 15504916] (ICC, Human)

Bioinformatics

• Gene Symbol: VCAM1